Related Experiment Videos
Iotrol, a new myelographic agent: 2. Comparative electroencephalographic evaluation by spectrum analysis
AJNR. American Journal of Neuroradiology
|May 1, 1983
Summary
Iotrol, a new contrast agent, showed no adverse effects in monkey EEG studies, unlike older agents like metrizamide and iopamidol. This suggests iotrol is a promising, safer option for subarachnoid space imaging.
Area of Science:
- Neuroradiology
- Neurophysiology
- Pharmacology
Background:
- Contrast media are essential for neuroradiological imaging.
- Evaluating the neurotoxicity of intrathecal contrast agents is crucial for patient safety.
- Nonionic dimer contrast agents offer potential advantages over ionic and non-ionic monomer agents.
Purpose of the Study:
- To compare the neurotoxicity of iotrol, a novel nonionic dimer, with existing contrast agents (metrizamide, iopamidol, iohexol).
- To assess the impact of these contrast agents on electroencephalography (EEG) in non-anesthetized primates.
Main Methods:
- Intrathecal administration of iotrol, metrizamide, iopamidol, and iohexol (300 mg I/ml) to cynomolgus monkeys.
- Electroencephalography (EEG) monitoring before and after contrast injection.
- Computerized analysis of EEG energy content and spectral analysis.
- Observation of behavioral and motor changes.
Main Results:
- Metrizamide and iopamidol induced seizures, lethargy, and behavioral changes.
- Iohexol caused transient apathy and motor disturbances.
- Iotrol did not produce any observable motor or behavioral changes.
- Metrizamide and iopamidol significantly altered EEG energy across all frequency bands.
- Iohexol and iotrol showed no significant impact on EEG.
Conclusions:
- Iotrol demonstrates a favorable neurotoxicity profile compared to metrizamide, iopamidol, and iohexol.
- Iotrol's lack of EEG alteration suggests it is a safe contrast agent for the subarachnoid space.
- Iotrol holds significant promise for clinical use in intrathecal imaging procedures.